Company profile: Ceptaris

1.1 - Company Overview

Ceptaris

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of a proprietary gel formulation of mechlorethamine hydrochloride under development for the treatment of early-stage (stages I–IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL); if approved, it would be the first topical treatment for this indication.

Products and services

🔒

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Ceptaris

AnPac Bio

HQ: United States Website

Description: Provider of early cancer screening and detection services, offering the CDA Early Cancer Risk Assessment using Cancer Differentiation Analysis to evaluate early cancer risks, the APCS Pan-Cancer Screening to detect multiple cancer types, and the ADME Third Immune Defense Test to assess immune defense capabilities against diseases, including cancer.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full AnPac Bio company profile →

FogPharma

HQ: United States Website

Description: Provider of precision medicines based on Helicons, a new class combining antibody-like targeting with broad tissue distribution and intracellular target engagement of small molecules; pipeline includes FOG-001, a first-in-class TCF-blocking β-catenin inhibitor (Phase 1/2), β-catenin and ERG degraders, an ERG/DNA binding inhibitor (discovery), and Helicon-enabled alpha radioligand therapies (hit identification).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full FogPharma company profile →

Immago

HQ: United Kingdom Website

Description: Provider of antibody-modulating enzyme approaches to enhance antibody-based cancer therapies, applying 'receptor refocusing' to modulate the endogenous antibody repertoire and enhance immune-mediated killing of cancer cells.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Immago company profile →

Insight Genetics

HQ: United States Website

Description: Provider of advanced molecular diagnostics for precision cancer care, delivering biopharma services with tissue- and blood-based technologies for biomarker-driven clinical trials; Multiplex PCR and Real Time PCR IVD development; proprietary immune therapy response assays; core lab IVD assay CDx support; target discovery using proprietary assays and NGS subclassification panels; assay design, development and validation.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Insight Genetics company profile →

Koya Medical

HQ: United States Website

Description: Provider of breakthrough treatments for lymphedema and venous diseases, as a transformative healthcare company.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Koya Medical company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Ceptaris

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Ceptaris

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Ceptaris's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Ceptaris's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Ceptaris

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Ceptaris's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Ceptaris's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Ceptaris

4.2 - Public trading comparable groups for Ceptaris

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Ceptaris

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Ceptaris

What does Ceptaris do?

Ceptaris is a provider of a proprietary gel formulation of mechlorethamine hydrochloride under development for the treatment of early-stage (stages I–IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL); if approved, it would be the first topical treatment for this indication.

Who are Ceptaris's competitors?

Ceptaris's competitors and similar companies include AnPac Bio, FogPharma, Immago, Insight Genetics, and Koya Medical.

Where is Ceptaris headquartered?

Ceptaris is headquartered in United States.

How many employees does Ceptaris have?

Ceptaris has 1,000 employees 🔒.

When was Ceptaris founded?

Ceptaris was founded in 2010 🔒.

What sector and industry vertical is Ceptaris in?

Ceptaris is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Ceptaris

Who are the top strategic acquirers in Ceptaris's sector and industry

Top strategic M&A buyers and acquirers in Ceptaris's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Ceptaris?

Top strategic M&A buyers groups and sectors for Ceptaris include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Ceptaris's sector and industry vertical

Which are the top PE firms investing in Ceptaris's sector and industry vertical?

Top PE firms investing in Ceptaris's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Ceptaris's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Ceptaris's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Ceptaris's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Ceptaris include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Ceptaris's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Ceptaris?

The key public trading comparables and valuation benchmarks for Ceptaris include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Ceptaris for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Ceptaris with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Ceptaris's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Ceptaris with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Ceptaris's' sector and industry vertical?

Access recent funding rounds and capital raises in Ceptaris's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Ceptaris

Start Free Trial Book a Demo